fashion -WSS

fashion

author：entertainment 2025-08-19 18:04:34 - browse：131

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How to convince healthy people to buy insurance

WSS

Device maker Teleflex to acquire urology company for $600M

CDC Director Mandy Cohen on transparency, trust, and health

Inari Medical to buy amputation prevention company LimFlow

Device maker Teleflex to acquire urology company for $600M

Prime Medicine says its gene editing passes test in monkeys

How doctors’ personal politics affect patients

entertainment

fashion

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Coloradans with cystic fibrosis could lose access to Trikafta

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: ESMO highlights & Roivant's big deal

The high cost of giving birth even with insurance

Medicare must police algorithms in Medicare Advantage, Dems say

ChatGPT in medicine: STAT answers readers' burning questions

The haunting brain science of long Covid

Medical leaders decry Supreme Court decision on affirmative action

Search called off for baby washed away in Pennsylvania flash flood

hotspot

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Search called off for baby washed away in Pennsylvania flash flood

Life sciences investors close nearly $6 billion in new funds

UHS says company favors patients whose insurance pays more

How doctors’ personal politics affect patients

Truvian presents data for its desktop blood

hotspot

explore

explore

focus